Thelansis’s "Muscle-Invasive Bladder Cancer (MIBC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Muscle-Invasive Bladder Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Muscle-invasive bladder cancer (MIBC) is an aggressive malignancy defined by urothelial carcinoma infiltrating the detrusor muscle layer of the bladder wall, heavily predisposing patients to microscopic systemic spread. Presentation typically features painless gross hematuria, pelvic pain, or irritative voiding. Transurethral resection of bladder tumor (TURBT) establishes muscle invasion, while cross-sectional CT/MRI and chest imaging provide staging. Molecularly, MIBC splits into distinct basal-like and luminal-like subtypes that dictate clinical behavior and chemosensitivity. For localized disease, the traditional standard remains neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy with lymphadenectomy. If patients harbor high-risk residual disease post-surgery, adjuvant nivolumab is standard—with 5-year CheckMate 274 data demonstrating nearly doubled disease-free survival, particularly when stratified by positive postsurgical ctDNA. Alternatively, concurrent chemoradiation via trimodality bladder preservation serves select candidates. Crucially, the standard of care for cisplatin-ineligible resectable MIBC has shifted entirely: the antibody-drug conjugate enfortumab vedotin plus pembrolizumab is no longer just a metastatic mainstay. Backed by Phase 3 EV-303/KEYNOTE-905 data, this combo is approved as a definitive perioperative regimen, cutting mortality by 50% and rewriting localized curative outcomes.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Muscle-Invasive Bladder Cancer (MIBC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Muscle-Invasive Bladder Cancer (MIBC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.